NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Part 1 of this study will establish a recommended Phase II (RPII) dose for the triplet
combination of NC-6004 plus 5-Fluorouracil (5-FU) and cetuximab. Part 2 will provide the
efficacy signal of the triplet combination in this patient population.